Business Wire

NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines

12.11.2019 05:50:00 EET | Business Wire | Press release

Share

NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191111005716/en/

Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial. NEC and VAXIMM will co-develop personalized cancer vaccines using NEC’s cutting-edge artificial intelligence (AI) technology, which is utilized in its Neoantigen Prediction System, and VAXIMM’s proprietary T-cell immunotherapy technology. The vaccines are planned to be evaluated in a Phase I clinical trial in various solid tumors. VAXIMM will be responsible for conducting the clinical trial, which is expected to be initiated in 2020.

NEC has the option for development and commercialization rights to the program worldwide, except for China and other Asian territories outside of Japan.

Osamu Fujikawa, Senior Vice President, NEC Corporation, said: “Cancer is consistently one of the most serious healthcare challenges, with millions of new cases diagnosed worldwide annually. NEC’s core technology is well positioned for the development of personalized medicine, and we are strongly committed to delivering effective treatments for cancer patients. We are delighted to be working with VAXIMM in order to develop an optimal immunotherapy for each individual patient.”

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of VAXIMM, said: “We are excited to enter this alliance with NEC and to have their strong support of VAXIMM. NEC’s novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient, facilitating the optimal potential treatment for each individual. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. Individualized therapy is at the cutting edge of cancer treatment today, and, with this collaboration, we are able to further contribute to this approach.”

Notes:

About NEC’s AI Drug Development Business
For more information, please visit https://www.nec.com/en/global/solutions/ai-drug/

About NEC's Neoantigen Prediction System
NEC’s neoantigen prediction utilizes its proprietary AI which is combined with NEC OncoImmunity AS’s bioinformatics pipelines – making it the leading neoantigen prediction system in the field. NEC comprehensively evaluates candidate neoantigens, which allows it to effectively prioritize numerous candidate neoantigens identified in a single patient.

Press release:
NEC acquires Norwegian bioinformatics company, OncoImmunity AS
https://www.nec.com/en/press/201907/global_20190729_01.html

About NEC Corporation
For more information, visit NEC at http://www.nec.com.

About VAXIMM
For more information, please see www.vaximm.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries
NEC Corporation
Joseph Jasper
Phone: +81 3 3798 6511
Email: j-jasper@ax.jp.nec.com

MC Services AG
Katja Arnold, Laurie Doyle
Phone: +49 89 210228 0
Email: vaximm@mc-services.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TTNE Announces the World Sauna Award “SAUNA37 2026”10.3.2026 05:00:00 EET | Press release

TTNE Inc. today announced “SAUNA37 2026”, the world sauna award recognizing 37 sauna destinations worldwide This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260308149186/en/ SAUNA37 Through this initiative, we aim to contribute to the global growth of sauna culture and create a future where people around the world can lead happier and healthier lives through saunas. TTNE was founded by Totonoe Oyakata (Dai Matsuo) and Sauna Master (Daisuke Akiyama), who have personally experienced some of the world's finest saunas. Their desire to establish a similar deep-rooted sauna culture in Japan led to the creation of TTNE. As people once again have the opportunity to explore sauna experiences around the world, SAUNA37 aims to introduce the diverse and unique sauna facilities and cultures across the globe. Through this initiative, we seek to further evolve Japan’s sauna culture while also sharing it with the world. TTNE remains committed

Hexagon Semi’s HX77 AR Display Processor Achieves Ultra-Low Power Consumption with VeriSilicon’s Nano IP Portfolio10.3.2026 02:00:00 EET | Press release

VeriSilicon (688521.SH) today announced that Hefei Hexagon Semiconductor (Hexagon Semi), an image processing SoC provider, has adopted VeriSilicon’s proven IP portfolio in its high-performance HX77 series image processing SoC. The adopted IPs include the GCNanoUltraV 2.5D Graphics Processing Unit (GPU) IP, DW100 DeWarp Processing IP, and DC9200Nano Display Processing IP. The SoC has successfully taped out, achieving a first-pass silicon success. The HX77 series is a highly integrated, low-power image processing SoC based on RISC-V architecture, integrating comprehensive video input/output interfaces, image processing, and system control capabilities. By leveraging an innovative heterogeneous computing architecture and sophisticated power management technology, HX77 has successfully achieved a technological breakthrough that enables 2K@60fps output with mere milliwatt-level power consumption. HX77 has also realized the 3DoF hover feature on end devices through spatial computing. In addi

Operio Group Named Distributor for Schaefer Technologies in the United Kingdom and European Union9.3.2026 23:00:00 EET | Press release

Operio Group has signed a distribution agreement with Schaefer Technologies, a manufacturer of semi-automatic encapsulation equipment. Operio Group, a holding company building a global group of brands serving the solid dose manufacturing industry, will be the official distributor of Schaefer Technologies’ products in the United Kingdom and the European Union. Schaefer Technologies develops semi-automatic capsule filling systems, including equipment that produces banded capsules for liquid and pellet formulations used by nutraceutical and pharmaceutical manufacturers. Leadership from both companies worked together to establish the agreement, including Kevin Schaefer, CEO of Schaefer Technologies Inc., and Alastair Sanderson, Chief Business Development Officer at Operio Group. “Schaefer Technologies is looking forward to our new relationship with Operio Group,” said Schaefer. “Their understanding of the pharmaceutical equipment market makes them a strong partner as we combine our experti

Kinaxis Goes All-In on Innovation at Upcoming Kinexions in Las Vegas9.3.2026 20:00:00 EET | Press release

Registration is officially open for Kinexions North America, the premier global supply chain orchestration conference hosted by Kinaxis® Inc. (TSX: KXS). Taking place June 1–3 in Las Vegas, Nevada, the event brings together supply chain leaders, innovators and practitioners from around the world to explore how organizations can leverage AI-driven strategies and technologies to connect data, people and decisions. After a year defined by market volatility, geopolitical risk and disruption, this year’s conference will focus on how intelligent supply chain orchestration enables organizations to move beyond reactive planning to building true enterprise adaptability. The program promises to be the most immersive and future-forward Kinexions yet, with renowned author, entrepreneur and innovation expert, Peter Hinssen confirmed as a featured keynote address. “Kinexions has always been the place where the best in supply chain come together to calibrate and share ideas, rethink what’s possible a

Radial Selects Riskified to Power Payment Fraud and Refund/Return Protection for Merchant Client Portfolio9.3.2026 16:00:00 EET | Press release

Riskified (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced a strategic partnership with Radial, a leading 3PL set to become Paxon later this year. Radial will integrate with Riskified’s AI-powered platform to help its merchants approve more legitimate orders and reduce losses from payment fraud, including many merchants that use Shopify as their ecommerce platform. Radial supports many of the world’s most recognized retail brands with a global ecommerce fulfillment network of more than 20 centers across North America, helping merchants deliver orders quickly and cost effectively. By bringing Riskified’s AI-powered fraud decisioning into its commerce ecosystem, Radial gives merchants the surgical ability to calibrate the checkout experience according to risk—without slowing fulfillment. This also supports brands seeking to expand into new markets. Riskified empowers Radial's customers with accurate, real-time fraud decisions at checkout, approving or decl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye